Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2014, Article ID 670475, 6 pages
http://dx.doi.org/10.1155/2014/670475
Clinical Study

Selective Vitamin D Receptor Activation as Anti-Inflammatory Target in Chronic Kidney Disease

1Research Unit, University Hospital Nuestra Señora de Candelaria, 38010 Santa Cruz de Tenerife, Spain
2GEENDIAB (Grupo Español para el Estudio de la Nefropatía Diabética) and REDINREN (RD12/0021/0019), Spain
3Nephrology Service, University Hospital Nuestra Señora de Candelaria, 38010 Santa Cruz de Tenerife, Spain
4Clinical Analysis Service, University Hospital Nuestra Señora de Candelaria, 38010 Santa Cruz de Tenerife, Spain

Received 3 October 2013; Revised 18 November 2013; Accepted 9 December 2013; Published 6 January 2014

Academic Editor: Jonathan Peake

Copyright © 2014 J. Donate-Correa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. S. Go, G. M. Chertow, D. Fan, C. E. McCulloch, and C.-Y. Hsu, “Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization,” The New England Journal of Medicine, vol. 351, no. 13, pp. 1296–1305, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. J. F. Navarro-González, C. Mora-Fernández, M. Muros, H. Herrera, and J. García, “Mineral metabolism and inflammation in chronic kidney disease patients: a cross-sectional study,” Clinical Journal of the American Society of Nephrology, vol. 4, pp. 1646–1654, 2009. View at Publisher · View at Google Scholar
  3. F. Tentori, M. J. Blayney, J. M. Albert et al., “Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS),” American Journal of Kidney Diseases, vol. 52, no. 3, pp. 519–530, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Levin, G. L. Bakris, M. Molitch et al., “Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease,” Kidney International, vol. 71, no. 1, pp. 31–38, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. M. S. Joy, P. C. Karagiannis, and F. W. Peyerl, “Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment,” Journal of Managed Care Pharmacy, vol. 13, no. 5, pp. 397–411, 2007. View at Google Scholar · View at Scopus
  6. T. V. Patel and A. K. Singh, “Role of vitamin D in chronic kidney disease,” Seminars in Nephrology, vol. 29, no. 2, pp. 113–121, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Dunlay, M. Rodriguez, A. J. Felsenfeld, and F. Llach, “Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis,” Kidney International, vol. 36, no. 6, pp. 1093–1098, 1989. View at Google Scholar · View at Scopus
  8. E. Slatopolsky, C. Weerts, J. Thielan, R. Horst, H. Harter, and K. J. Martin, “Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients,” Journal of Clinical Investigation, vol. 74, no. 6, pp. 2136–2143, 1984. View at Google Scholar · View at Scopus
  9. M. Teng, M. Wolf, E. Lowrie, N. Ofsthun, J. M. Lazarus, and R. Thadhani, “Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy,” The New England Journal of Medicine, vol. 349, no. 5, pp. 446–456, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. C. S. Shinaberger, J. D. Kopple, C. P. Kovesdy et al., “Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients,” Clinical Journal of the American Society of Nephrology, vol. 3, no. 6, pp. 1769–1776, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Russell, D. Lettieri, and L. M. Sherwood, “Suppression by 1,25(OH)2D3 of transcription of the pre-proparathyroid hormone gene,” Endocrinology, vol. 119, no. 6, pp. 2864–2866, 1986. View at Google Scholar · View at Scopus
  12. J. Silver, J. Russell, and L. M. Sherwood, “Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 82, no. 12, pp. 4270–4273, 1985. View at Google Scholar · View at Scopus
  13. M. J. Izquierdo, M. Cavia, P. Muñiz et al., “Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients,” BMC Nephrology, vol. 27, no. 13, article 159, 2012. View at Google Scholar
  14. C. Piñera-Haces, M. J. Izquierdo-Ortiz, L. Á. Martín-de Francisco et al., “Double treatment with paricalcitol-associated calcifediol and cardiovascular risk biomarkers in haemodialysis,” Nefrología, vol. 18, no. 33, pp. 77–84, 2013. View at Google Scholar
  15. J. F. Navarro-González, J. Donate-Correa, M. L. Méndez, M. M. de Fuentes, J. García-Pérez, and C. Mora-Fernández, “Anti-inflammatory profile of paricalcitol in hemodialysis patients: a prospective, open-label, pilot study,” The Journal of Clinical Pharmacology, vol. 53, pp. 421–426, 2013. View at Google Scholar
  16. K. J. Martin, E. A. González, M. Gellens, L. L. Hamm, H. Abboud, and J. Lindberg, “19-nor-1-α-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis,” Journal of the American Society of Nephrology, vol. 9, no. 8, pp. 1427–1432, 1998. View at Google Scholar · View at Scopus
  17. J. G. Hervás Sánchez, M. D. Prados Garrido, A. Polo Moyano, and S. Cerezo Morales, “Effectiveness of treatment with oral paricalcitol in patients with pre-dialysis chronic kidney disease,” Nefrologia, vol. 31, no. 6, pp. 697–706, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Hadjiyannakos, V. Filipoulos, S. Trompouki et al., “Tretament with oral paricalcitol in daily clinical practice for patients with chronic kidney disease stage 3-4: a preliminary study,” Clinical Kidney Journal, vol. 6, pp. 164–168, 2013. View at Google Scholar
  19. D. Andress, “Nonclassical aspects of differential vitamin D receptor activation: Implications for survival in patients with chronic kidney disease,” Drugs, vol. 67, no. 14, pp. 1999–2012, 2007. View at Google Scholar · View at Scopus
  20. A. S. Dusso, A. J. Brown, and E. Slatopolsky, “Vitamin D,” American Journal of Physiology: Renal Physiology, vol. 289, no. 1, pp. F8–F28, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Lin and J. H. White, “The pleiotropic actions of vitamin D,” BioEssays, vol. 26, no. 1, pp. 21–28, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. M. D. Sánchez-Niño, M. Bozic, E. Córdoba-Lanus et al., “Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy,” American Journal of Physiology: Renal Physiology, vol. 302, pp. 647–657, 2011. View at Google Scholar
  23. X. Tan, X. Wen, and Y. Liu, “Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-κB signaling,” Journal of the American Society of Nephrology, vol. 19, no. 9, pp. 1741–1752, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. C. S. Kim, S. Y. Joo, K. E. Lee et al., “Paricalcitol attenuates 4-hydroxy-2-hexenal-induced inflammation and epithelial-mesenchymal transition in human renal proximal tubular epithelial cells,” PLoS ONE, vol. 17, no. 8, Article ID e63186, 2013. View at Google Scholar
  25. P. Alborzi, N. A. Patel, C. Peterson et al., “Paricalcitol reduces albuminuria and inflammation in chronic kidney disease a randomized double-blind pilot trial,” Hypertension, vol. 52, no. 2, pp. 249–255, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Eleftheriadis, G. Antoniadi, V. Liakopoulos, C. Kartsios, I. Stefanidis, and G. Galaktidou, “Paricalcitol reduces basal and lipopolysaccharide-induced (LPS) TNF-α and IL-8 production by human peripheral blood mononuclear cells,” International Urology and Nephrology, vol. 42, no. 1, pp. 181–185, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Zoccali, G. Tripepi, and F. Mallamaci, “Dissecting inflammation in ESRD: do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients?” Journal of the American Society of Nephrology, vol. 17, no. 3, pp. S169–S173, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Kessler, F. Zannad, P. Lehert et al., “Predictors of cardiovascular events in patients with end-stage renal disease: an analysis from the Fosinopril in Dialysis study,” Nephrology Dialysis Transplantation, vol. 22, no. 12, pp. 3573–3579, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. R. S. Parekh, L. C. Plantinga, W. H. L. Kao et al., “The association of sudden cardiac death with inflammation and other traditional risk factors,” Kidney International, vol. 74, no. 10, pp. 1335–1342, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Ramirez, J. Carracedo, I. Berdud et al., “Microinflammation in hemodialysis is related to a preactivated subset of monocytes,” Hemodialysis International, vol. 10, no. 1, pp. S24–S27, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Kostulas, S. H. Pelidou, P. Kivisäkk, V. Kostulas, and H. Link, “Increased IL-1β, IL-8, and IL-17 mRNA expression in blood mononuclear cells observed in a prospective ischemic stroke study,” Stroke, vol. 30, no. 10, pp. 2174–2179, 1999. View at Google Scholar · View at Scopus
  32. T. Akatsu, M. Nakamura, M. Satoh, and K. Hiramori, “Increased mRNA expression of tumour necrosis factor-α and its converting enzyme in circulating leucocytes of patients with acute myocardial infarction,” Clinical Science, vol. 105, no. 1, pp. 39–44, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. D. G. Dobrez, A. Mathes, M. Amdahl, S. E. Marx, J. Z. Melnick, and S. M. Sprague, “Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings,” Nephrology Dialysis Transplantation, vol. 19, no. 5, pp. 1174–1181, 2004. View at Publisher · View at Google Scholar · View at Scopus